ClinVar Miner

Submissions for variant NM_000492.4(CFTR):c.825C>G (p.Tyr275Ter)

gnomAD frequency: 0.00001  dbSNP: rs193922532
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
CFTR2 RCV000029545 SCV000677629 pathogenic Cystic fibrosis 2017-03-17 reviewed by expert panel research
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000029545 SCV000052197 pathogenic Cystic fibrosis 2021-03-04 criteria provided, single submitter clinical testing Variant summary: CFTR c.825C>G (p.Tyr275X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 249138 control chromosomes. c.825C>G has been reported in the literature in individuals affected with Classic Cystic Fibrosis (Bernardino 2000, McGinniss 2005, Claustres 2017, Dankert-Roelse 2018). These data indicate that the variant is likely to be associated with disease. At least one publication reported experimental evidence, evaluating the basal and drug induced read-through levels of this premature termination codon, and reported less than 0.5% basal read-through activities and low levels of drug induced responses (Pranke 2018). Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Mendelics RCV000029545 SCV000886287 pathogenic Cystic fibrosis 2018-11-05 criteria provided, single submitter clinical testing
Baylor Genetics RCV001004239 SCV001163115 pathogenic Cystic fibrosis; Congenital bilateral aplasia of vas deferens from CFTR mutation criteria provided, single submitter clinical testing
CFTR-France RCV000029545 SCV001169333 pathogenic Cystic fibrosis 2018-01-29 criteria provided, single submitter curation
Labcorp Genetics (formerly Invitae), Labcorp RCV000029545 SCV002233679 pathogenic Cystic fibrosis 2023-12-09 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Tyr275*) in the CFTR gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CFTR are known to be pathogenic (PMID: 1695717, 7691345, 9725922). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with cystic fibrosis (PMID: 10794365, 16963320). ClinVar contains an entry for this variant (Variation ID: 35890). For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV000029545 SCV002681038 pathogenic Cystic fibrosis 2019-09-11 criteria provided, single submitter clinical testing The p.Y275* pathogenic mutation (also known as c.825C>G) located in coding exon 7 of the CFTR gene, results from a C to G substitution at nucleotide position 825. This changes the amino acid from a tyrosine to a stop codon within coding exon 7. This mutation was originally described newborn with severe disease who is also heterozygous for p.F508del (Bernardino AL et al. Genet Test. 2000;4:69-74). It was later reported in a 3 year old with positive sweat chlorides and classic CF presentation (McGinniss et al Hum Genet 2005; 118: 331-338) as well as in a newborn with elevated sweat chloride levels and a second disease causing allele (Dankert-Roelse JE et al. J. Cyst. Fibros., 2019 Jan;18:54-63). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Baylor Genetics RCV003473146 SCV004213497 pathogenic Bronchiectasis with or without elevated sweat chloride 1 2023-11-20 criteria provided, single submitter clinical testing
Counsyl RCV000029545 SCV001132150 likely pathogenic Cystic fibrosis 2017-09-22 no assertion criteria provided clinical testing
Natera, Inc. RCV001831612 SCV002078143 pathogenic CFTR-related disorder 2017-03-17 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.